CN116782912A - 5'-o-苯乙酰基尿苷及其治疗用途 - Google Patents

5'-o-苯乙酰基尿苷及其治疗用途 Download PDF

Info

Publication number
CN116782912A
CN116782912A CN202180080169.0A CN202180080169A CN116782912A CN 116782912 A CN116782912 A CN 116782912A CN 202180080169 A CN202180080169 A CN 202180080169A CN 116782912 A CN116782912 A CN 116782912A
Authority
CN
China
Prior art keywords
compound
uridine
disorder
mammalian subject
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180080169.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·加西亚·加西亚
J·A·赛多夫
D·M·辛普森
R·W·范博斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaceutical Co ltd
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of CN116782912A publication Critical patent/CN116782912A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
CN202180080169.0A 2020-12-01 2021-11-30 5'-o-苯乙酰基尿苷及其治疗用途 Pending CN116782912A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119764P 2020-12-01 2020-12-01
US63/119,764 2020-12-01
PCT/US2021/061053 WO2022119784A1 (en) 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use

Publications (1)

Publication Number Publication Date
CN116782912A true CN116782912A (zh) 2023-09-19

Family

ID=81854225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180080169.0A Pending CN116782912A (zh) 2020-12-01 2021-11-30 5'-o-苯乙酰基尿苷及其治疗用途

Country Status (16)

Country Link
US (1) US20230416292A1 (https=)
EP (2) EP4255563B1 (https=)
JP (1) JP2023551467A (https=)
KR (1) KR20230112118A (https=)
CN (1) CN116782912A (https=)
AU (1) AU2021391411A1 (https=)
BR (1) BR112023010517A2 (https=)
CA (1) CA3199559A1 (https=)
DK (1) DK4255563T3 (https=)
FI (1) FI4255563T3 (https=)
IL (1) IL303100A (https=)
LT (1) LT4255563T (https=)
MX (1) MX2023006343A (https=)
PL (1) PL4255563T3 (https=)
PT (1) PT4255563T (https=)
WO (1) WO2022119784A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4210709T (pt) 2020-09-14 2026-02-04 Pharma Cinq Llc 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿
TW202317144A (zh) * 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585512A (en) * 1994-05-20 1996-12-17 Director-General Of Agency Of Industrial Science And Technology Esters of p-hydroxyaniline mustard
CN101102816A (zh) * 2004-11-26 2008-01-09 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸（phenylacetate)或苯基丁酸（phenylbutyrate)的组合物
CN102512408A (zh) * 2004-11-26 2012-06-27 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物
CN104797272A (zh) * 2012-11-21 2015-07-22 海波龙治疗公司 施用及评价用于治疗肝性脑病的氮清除药物的方法
CN111601589A (zh) * 2018-02-01 2020-08-28 维尔斯达医疗公司 用于全身性递送尿苷的组合物和装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
EP1808177B1 (en) * 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
PL3182980T3 (pl) * 2014-08-19 2021-04-19 Wellstat Therapeutics Corporation Leczenie chorób niedoboru glikozylacji
WO2022089612A1 (zh) * 2020-10-30 2022-05-05 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585512A (en) * 1994-05-20 1996-12-17 Director-General Of Agency Of Industrial Science And Technology Esters of p-hydroxyaniline mustard
CN101102816A (zh) * 2004-11-26 2008-01-09 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸（phenylacetate)或苯基丁酸（phenylbutyrate)的组合物
CN102512408A (zh) * 2004-11-26 2012-06-27 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物
CN104797272A (zh) * 2012-11-21 2015-07-22 海波龙治疗公司 施用及评价用于治疗肝性脑病的氮清除药物的方法
CN111601589A (zh) * 2018-02-01 2020-08-28 维尔斯达医疗公司 用于全身性递送尿苷的组合物和装置

Also Published As

Publication number Publication date
PL4255563T3 (pl) 2026-04-20
EP4255563B1 (en) 2025-12-31
WO2022119784A1 (en) 2022-06-09
JP2023551467A (ja) 2023-12-08
AU2021391411A1 (en) 2023-07-20
IL303100A (en) 2023-07-01
EP4711007A2 (en) 2026-03-18
PT4255563T (pt) 2026-03-24
MX2023006343A (es) 2023-06-12
BR112023010517A2 (pt) 2024-02-06
KR20230112118A (ko) 2023-07-26
EP4255563A1 (en) 2023-10-11
FI4255563T3 (fi) 2026-03-13
EP4711007A3 (en) 2026-04-01
AU2021391411A9 (en) 2024-07-18
CA3199559A1 (en) 2022-06-09
EP4255563A4 (en) 2024-09-11
DK4255563T3 (da) 2026-03-16
LT4255563T (lt) 2026-04-10
US20230416292A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP2637534B2 (ja) アシルデオキシリボヌクレオシド誘導体およびその使用
EP0601322A2 (en) Adenosindeaminase inhibitor
MC1992A1 (fr) Derives de fluorocytidine
JPH07501539A (ja) Ｎ，ｎ’−ジアセチルシスチンの有機塩
EP2407474B1 (en) Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat
CN116782912A (zh) 5'-o-苯乙酰基尿苷及其治疗用途
CN101704874A (zh) 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
US7985774B2 (en) Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug
JP2650756B2 (ja) 皮膚および粘膜上皮の疾患の治療のための４‐キノリンカルボン酸誘導体
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
PT2070940E (pt) Conjugados de macrólidos com actividade anti-inflamatória
FI91156C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
EP4210709B1 (en) 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
CN110183504A (zh) 一种具有肿瘤靶向性的吉西他滨前体药物及其制备方法和用途
US4508733A (en) Drug for stimulating hepatic cell homeostasis and for restoring the functional capacity of the hepatocytes
JPH01199961A (ja) タウリン誘導体、その製法及びこれを含有する薬剤組成物
US12357641B2 (en) Identification of oleanolic acid and plant extract for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy
JPH05502889A (ja) 新規アデノシン誘導体、その製造および使用法
HK40097085A (en) 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
HK40097085B (en) 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
US4511580A (en) Drug for stimulating hepatic cell homeostasis and for restoring the functional capacity of the hepatocytes
JPS6254422B2 (https=)
CN110590838A (zh) Y27632前药、其制备方法及其在医药上的应用
JP2005534666A (ja) アデノウイルス及びｈｉｖに対して選択的活性を有するアリールホスフェート誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240617

Address after: American Maryland

Applicant after: Pharmaceutical Co.,Ltd.

Country or region after: U.S.A.

Address before: American Maryland

Applicant before: Wellstat Therapeutics Corp.

Country or region before: U.S.A.